Clinical Trial: Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer

U.S., May 13 -- ClinicalTrials.gov registry received information related to the study (NCT07579221) titled 'Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer' on May 07.

Brief Summary: The goal of this clinical research study is to find a safe and tolerable dose of navlimetostat in combination with pumitamig that can be given to patients with MTAP-deficient advanced non-small cell lung cancer (NSCLC). The effectiveness of the study drugs will also be studied.

Study Start Date: Nov. 30, 2026

Study Type: INTERVENTIONAL

Condition: Non-Small Cell Lung Cancer

Intervention: DRUG: Navlimetostat

Given orally once daily

DRUG: Pumitamig

Given by infusion

Recruitment Status: NOT_YET_RECRUITING...